Cytokinetics, Incorporated · NASDAQ:CYTK
Cytokinetics — Technical Presentation (November 2025)
18 slides from Cytokinetics's technical presentation, Nov 6, 2025
Slide 1: Long-Term Impact of Aficamten on Patient-Reported Outcome Measures in Obstructive HCM
LONG-TERM IMPACT OF AFICAMTEN ON PATIENT-REPORTED OUTCOME MEASURES IN OBSTRUCTIVE HCM Shepard D. Weiner1, Lusha W. Liang, Ahmad Masri, Theodore P. Abraham, Roberto Barriales-Villa, Robert M. Cooper, Perry M. Elliott, Alejandro de Feria, Martin S. Maron, Artur Oreziak, Sara Saberi, Scott D. Solomon,
Slide 2: Disclosures & Acknowledgments
DISCLOSURES & ACKNOWLEDGMENTS • Shepard D. Weiner has received consulting fees from Cytokinetics and Bristol Myers Squibb • The FOREST-HCM trial was funded by Cytokinetics, Incorporated • Editorial support for the preparation of this presentation was provided by David Sunter PhD, on behalf of Engage
Slide 3: Background
01 BACKGROUND #AHA25 3
Slide 4: Hypertrophic cardiomyopathy background and symptoms
• Hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disorder characterized by enhanced actin-myosin interactions1,2 • Left ventricular (LV) hypertrophy • Diastolic dysfunction • LV outflow tract (LVOT) obstruction • Patients with obstructive HCM (oHCM) can experience functional impairm
Slide 5: SEQUOIA-HCM patient-reported outcomes over 24 weeks
Treatment with aficamten in patients with oHCM led to significant improvements in patient-reported outcomes in the SEQUOIA-HCM trial over 24 weeks4 Mean Kansas City Cardiomyopathy Questionnaire Mean Seattle Angina Questionnaire Overall Summary Scores (KCCQ-OSS) Summary Scores (SAQ7-SS) ∆KCCQ-OSS = 7
Slide 6: Methods
02 METHODS #AHA25 6
Slide 7: FOREST-HCM study design
FOREST-HCM • FOREST-HCM (NCT04848506) is an ongoing, open-label extension study for eligible patients who participated in clinical trials of aficamten. • Participants started on aficamten 5 mg daily, adjusted in 5-mg increments up to 20 mg at ≥2-week intervals according to site-read echocardiographi
Slide 8: Patient-Reported Outcome Measures
PATIENT-REPORTED OUTCOME MEASURES • Kansas City Cardiomyopathy Questionnaire (KCCQ)5 o Developed for patients with heart failure but recently validated in HCM.6 • Seattle Angina Questionnaire (SAQ7)7 o Developed for patients with chest pain from coronary artery disease. • EuroQol 5-dimensional Quest
Slide 9: Results
03 RESULTS #AHA25 9
Slide 10: Baseline Characteristics and Dosing
BASELINE CHARACTERISTICS AND DOSING Baseline characteristics* n=172 Dosages of aficamten Age (year) 60 ± 13 at Week 48 Female 78 (45) Prior AF 37 (22) NYHA functional class 5% I 1 (1) II 103 (60) 16% III 68 (39) IV 0 LVOT gradient at rest, mmHg 58 ± 38 52% LVOT gradient with Valsalva, mmHg 93 ± 40 2
Slide 11: KCCQ Response Over Time
KCCQ RESPONSE OVER TIME Improvements seen across all domains in KCCQ, as early as 12 weeks and sustained through 48 weeks. 30 25 Change from baseline KCCQ domains* 20 Quality of life Overall summary score Total symptom score 15 Physical limitation score 10 5 0 0 12 24 36 48 Weeks *P<0.001 for change
Slide 12: SAQ7 change from baseline
SAQ7 Improvements seen across all domains in SAQ7 as early as 12 weeks and sustained through 48 weeks. 30 Change from baseline in SAQ7 25 20 SAQ7 domains* Quality of life Physical limitation 15 Summary score Angina frequency 10 5 0 0 12 24 36 48 Weeks Minimally clinically important difference = 5 po
Slide 13: EQ-5D-5L VAS and Index
EQ-VAS EQ-5D-5L INDEX 0 100 Worst Best imaginable imaginable health health • Improvements noted across all 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and 15 anxiety/depression. Change from baseline in • Most notably, at baseline, 47.7% of EQ-5D-5L VAS 10 participants repor
Slide 14: PGIC and CGI-I
PGIC AND CGI-I At week 48, 77% of participants reported feeling either “Much Improved” or “Very Much Improved” based on the PGIC. 84% of treating clinicians reported their patients were either “Much Improved” or “Very Much Improved” based on the CGI-I. 100 40 PGIC CGI-I 30 Participants (%) 20 10 0 V
Slide 15: Discussion
04 DISCUSSION #AHA25 15
Slide 16: Limitations
LIMITATIONS • Open label design • Despite use of multiple PROs, not all domains of patient experience may have been fully captured. 16
Slide 17: Conclusion
CONCLUSION • Treatment with aficamten in patients with oHCM was associated with significant and sustained improvements in multiple PROs over 48 weeks, particularly in quality of life. • These findings extend the results of SEQUOIA-HCM by demonstrating meaningful and durable health status improvement
Slide 18: Thank You
THANK YOU 333 Scientific ‘=? Sessions #AHA25
Cytokinetics — Technical Presentation (November 2025) on 6ix